Cobxbio
5 known investors
CoBX Bio is a drug discovery company working in chemical proteomics. The available page content is limited to legal notices and a tagline, offering little detail about specific programs or products.
Also known as CoBX Bio · CoBX Bio, Inc. · COBXBio
Investors · 5
Also in the syndicate · 4
Company profile
researched Aug 2026CoBX Bio, Inc. is a biotechnology and pharmaceutical research company based in Seoul, South Korea, founded in 2024. It researches and develops covalent bond inhibitors and molecular adhesive (molecular glue) degraders intended to address limitations of existing small-molecule medicines, including drug resistance and insufficient efficacy, by forming stronger attachments to disease-associated proteins.
The company's disclosed pipeline includes covalent inhibitors targeting Menin, a protein derived from MEN1, and molecular adhesive degraders directed at GSPT1, a protein associated with cancer cell survival. Proceeds from its September 2025 financing were earmarked for development of Menin inhibitors and E3 ligase inhibitors. Corporate website sections indicate planned areas of activity spanning investor relations materials, clinical updates, business news and research updates.
Founding story
CoBX Bio was established in 2024 in Seoul, South Korea. It was founded by a team comprising CEO Choi Hwan-geun (Hwan-geun Choi), CEO Kim Nam-doo (Nam-du Kim) and Vice President Son Jeong-beom. Hwan Geun Choi, listed with CoBX Bio and a verified cobxbio.com email address, has a publication record in chemoproteomics, drug discovery and medicinal chemistry, including work on kinase inhibitors, covalent K-Ras inhibitors, EGFR inhibitor resistance and chemoproteomic degrader approaches.
Traction
CoBX Bio reported a pre-Series A financing of KRW 7.6 billion in September 2025 from a syndicate of Korean institutional investors, with proceeds directed toward Menin inhibitor and E3 ligase inhibitor development. Disclosed programs remain at the discovery/preclinical stage.
Latest developments
In September 2025 the company closed a pre-Series A round of KRW 7.6 billion from Korea Investment Partners, Laplace Partners, Solid X, Solidus Investment, Company K Partners, KB Investment and UTC Investment, to be applied to Menin inhibitor and E3 ligase inhibitor development.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company is classified in biotechnology and pharmaceuticals, with sub-industry categorization spanning biopharmaceuticals, bioinformatics, pharmaceutical research and development, and specialty pharmaceuticals. It is tracked by industry data providers including Citeline/Biomedtracker and Preqin.
Technology
CoBX Bio's proprietary platform, RaPIDome, integrates chemical proteomics, molecular modeling and artificial intelligence to identify drug mechanisms of action and resistance pathways. The technology is applied to two modalities: covalent bond inhibitors, which bind disease-related proteins more strongly than conventional reversible inhibitors, and molecular adhesive degraders designed to induce degradation of target proteins.
Go-to-market
As a preclinical-stage drug discovery company, its programs address oncology indications, including targets linked to cancer cell survival such as GSPT1 and Menin.
Geography
Headquarters and operations are in Seoul, South Korea.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsCoBX Bio raised KRW 7.6 billion in pre-Series A funding from Korea Investment Partners, Laplace Partners, Solid X, Solidus Investment, Company K Partners, KB Investment and UTC Investment, to be used for development of Menin inhibitors and E3 ligase inhibitors.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Cobxbiocobxbio.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Cobxbio do?
- CoBX Bio is a Seoul-based drug discovery company developing covalent inhibitors and molecular glue degraders.
- Who are Cobxbio's investors?
- Cobxbio's investors include Atinum Investment Co. Ltd..